Printer Friendly

BRISTOL-MYERS SQUIBB TO INTRODUCE PRAVACHOL, CHOLESTEROL-LOWERING AGENT

BRISTOL-MYERS SQUIBB TO INTRODUCE PRAVACHOL, CHOLESTEROL-LOWERING AGENT
 WHO: Bristol-Myers Squibb Company
 WHAT: To announce the introduction of Pravachol(R) (pravastatin sodium), the latest entry in the cholesterol-lowering market.
 WHERE: The Pierre Hotel, Cotillion Room, second floor,
 Fifth Avenue at 61st Street
 New York City, 212-838-8000
 Free valet parking will be available. Bring tickets to the press conference registration table for validation.
 WHEN: 9:00 a.m. EST, Nov. 7, 1991
 -- 8:30 to 9:00 Continental Breakfast
 -- 9:00 to 10:30 Press conference
 -- Brunch to follow.
 WHY: To introduce Pravachol and provide the latest scientific information on the importance of the management of high cholesterol levels.
 SPEAKERS:
 -- Kenneth E. Weg, president, Bristol-Myers Squibb Pharmaceutical Group
 -- Kenneth M. Given, M.D., senior vice president, Worldwide Regulatory Affairs, Bristol-Myers Squibb Pharmaceutical Research Institute.
 -- Antonio M. Gotto, Jr., M.D., D.Phil., chairman, Department of Medicine, Baylor College of Medicine; chief of Internal Medicine Service, the Methodist Hospital, Houston.
 -- John C. LaRosa, M.D., F.A.C.P., dean for research, George Washington Medical Center; director, Lipid Research Clinic, the George Washington University Medical Center, Washington,
 -- Ernst J. Schaefer, M.D., professor of medicine, Tufts University School of Medicine; director, Lipid Clinic, New England Medical Center; Boston.
 Immediately following the Pravachol press conference, there will be a
question-and-answer session. Media can call in questions at:


800-666-8009
 BROADCAST MEDIA: Press conference downlink information
 DATE: Nov. 7, 1991
 TIME: 9:00 - 10:30 a.m. (EST) Press Conference & Live Q&A
 11:00 - 11:30 a.m. (EST) Video News Story, including
 bites and b-roll
 SATELLITE COORDINATES:
 Ku Band: SBS 6, Transponder 10 C Band: Galaxy 6, Transponder 8
 6.2 & 6.8 Dual Audio 6.2 & 6.8 Dual Audio
 The entire satellite press conference, Q&A session and video news story will re-feed in its entirety on the same coordinates at:
 RE-FEED: 11:00 a.m. - 1:00 p.m. (EST)
 RADIO AVAILABILITY: Media wishing to record the program can access audio feed by calling: 800-541-1897.
 Requests for a copy of the product describing information for Pravachol(R) (pravastatin sodium) should be directed to the Bristol- Myers Squibb Professional Services Department at 800-321-1335.
 CONTACT and RSVP: Elizabeth Borrelli, 212-951-5437, or Kelly Mansfield, 212-951-5468, both of Ogilvy & Mather, for Bristol-Myers Squibb. RVSP by Nov. 6.
 -0- 11/6/91
 (BMY) CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU: SM-TJ -- NY001 -- 1535 11/06/91 08:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:406
Previous Article:SAINSBURY ANNOUNCES INTERIM RESULTS
Next Article:INTEGRATED HEALTH SERVICES ANNOUNCES MEDICAL SPECIALTY UNIT DEVELOPMENT PLAN FOR 1992; COMPANY TO INCREASE MSUs BY 60 PERCENT FOR 1992
Topics:


Related Articles
BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL: A NEW CHOLESTEROL-LOWERING THERAPY
BRISTOL-MYERS SQUIBB INTRODUCES PRAVACHOL, A NEW CHOLESTEROL-LOWERING THERAPY
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC
BRISTOL-MYERS SQUIBB INTRODUCES CEFZIL(TM), A NEW ORAL ANTIBIOTIC (Product Announcement)
BRISTOL-MYERS SQUIBB STATEMENT REGARDING PUBLICATION OF KOBASHIGAWA STUDY IN SEPTEMBER 7 ISSUE OF NEW ENGLAND JOURNAL OF MEDICINE
FDA CLEARS PRAVACHOL(R) TO REDUCE RISK OF HEART ATTACK AND SLOW PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH ELEVATED CHOLESTEROL AND HEART DISEASE
FDA CLEARS PRAVACHOL(R) TO HELP PREVENT FIRST HEART ATTACK AND REDUCE DEATH FROM CARDIOVASCULAR DISEASE IN PATIENTS WITH ELEVATED CHOLESTEROL
Pravachol Reduces Risk of Recurrent Heart Attack and Death From Heart Disease According to Study Published in Latest Issue of the New England Journal...
Bristol-Myers Squibb Statement Regarding 'The Relationship Between LDL-C Changes and Coronary Heart Disease Event Reduction in the West of Scotland...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters